Wegovy Side Effects: Common Symptoms, Serious Risks and Form Differences
A current guide to Wegovy side effects, urgent warning signs and the different U.S. and U.K. injection, tablet and age contexts.
Wegovy Side Effects
Common Wegovy side effects are mainly gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal symptoms appear prominently in current product information, alongside effects such as headache and fatigue. But there is no single worldwide Wegovy rate: the United States and United Kingdom now have separate injection and tablet contexts, and the U.S. adolescent weight-management evidence applies to injection rather than tablets. Severe persistent abdominal pain, serious allergy, inability to keep fluids down, severe low glucose in a relevant medicine combination, or sudden or rapidly worsening vision needs prompt or urgent assessment.
Timeline at a glance
Wegovy is no longer accurately described as one global injection-only profile. Start with country, route, age and indication; keep each symptom and its functional impact separate; and let urgent warning signs override any planned timeline.
Fix country, form and age
Record whether the supplied product is U.S. or U.K. injection or tablets and whether the person is an adult or adolescent. Form-specific evidence and instructions must not be pooled.
Track digestive tolerance and hydration
Record nausea, vomiting, diarrhoea, constipation, abdominal symptoms, headache, fatigue, food tolerance, fluids, dizziness and urine separately. A frequency category does not predict one person's severity or duration.
Add glucose, vision and procedure context
Insulin or a sulfonylurea can change low-glucose risk. Diabetic retinopathy, new vision symptoms, severe gastroparesis and planned anaesthesia need their own clinical context.
Urgent signs bypass the timeline
Severe persistent abdominal pain, serious allergy, fainting, severe low glucose, inability to hydrate or sudden or rapidly worsening vision should not wait for a scheduled checkpoint.
The bars show relative visibility within this guide only. They are not percentages, clinical measurements or personal forecasts.
Why Wegovy side effects need country, form and age
Wegovy contains semaglutide. Effects on appetite, glucose regulation and gastric emptying help explain digestive and procedure-related label content, but they cannot predict one person's course or authorize a treatment change.
The United States and United Kingdom now publish separate injection and tablet contexts. The U.S. weight-management evidence from age 12 applies to injection, while tablet safety and effectiveness are not established in pediatric patients.
Common and urgent are parallel lanes. Digestive symptoms can be common, yet dehydration, severe persistent pain, serious allergy, relevant low glucose or vision change can alter the action boundary immediately.
Deeper visual interpretation
A useful Wegovy side-effect answer starts with a four-part identity check: country, injection or tablet, adult or adolescent, and licensed indication. Shared semaglutide does not turn those contexts into one frequency table or one instruction set.
| Context | Route and population | Evidence boundary |
|---|---|---|
| United States injection | Weekly injection; adult uses plus weight management from age 12 in defined patients | Adult and adolescent programs remain population-specific |
| United States tablets | Daily oral product for defined adult uses | Pediatric safety and effectiveness are not established |
| United Kingdom injection | Injection under current local eligibility and product information | Use the supplied strength and leaflet; do not import U.S. percentages |
| United Kingdom tablets | Oral Wegovy authorized for eligible adults | A distinct adult tablet leaflet; authorization does not make routes equivalent |
| Track | What to record | Action boundary |
|---|---|---|
| Digestive and hydration | Nausea, vomiting, diarrhoea, constipation, abdominal symptoms, food, fluids, dizziness and urine | Persistence, severity or inability to hydrate needs prompt advice; severe persistent pain is urgent |
| Glucose | Existing readings and symptoms with insulin or a sulfonylurea | Follow the established plan; the article does not change medicines |
| Vision | Retinopathy history, eye affected, sudden or gradual change, pain and onset | Sudden loss or rapid worsening requires urgent assessment |
| Procedure and product | Anaesthesia, severe gastroparesis, oral medicines, pregnancy and exact supply | Tell responsible teams and use the local leaflet before any change |
Build a form-preserving Wegovy record
- Write country, route and age first
These fields determine which indication, evidence set and patient leaflet can be used.
- Copy the exact supplied product
Keep the strength, licensed pharmacy, prescriber and leaflet revision with the record.
- Split digestive observations
Give nausea, vomiting, diarrhoea, constipation, pain, food, fluids, headache and fatigue separate timing and impact fields.
- Add glucose, eye and procedure context
Record relevant medicines, retinopathy or vision change, severe gastric disease and planned anaesthesia independently.
- Close the clinical loop
Document advice and symptom direction without inventing a dose, missed-dose, restart or form-conversion decision.
How to interpret the stages
A recovery timeline combines broad observations from published patient guidance. It cannot know the exact product or device, treatment depth, technique, medical history, skin characteristics or aftercare plan involved in one person’s case.
Use the stages to understand the order in which changes may happen and to prepare questions for a qualified professional. Do not use a general internet timeline to override instructions from the clinician who assessed and treated you.
Aftercare principles
- Write country, Wegovy injection or tablets, age group, indication, strength, prescriber and current label before interpreting any frequency.
- Log nausea, vomiting, diarrhoea, constipation, pain, food and fluid tolerance, dizziness, headache, fatigue and urine change as separate entries with onset, duration and functional impact.
- Follow the existing glucose plan when insulin or a sulfonylurea is also used. This page does not calculate medicine adjustments.
- Record diabetic retinopathy and every new or worsening vision symptom separately; sudden loss or rapid worsening requires urgent assessment under local guidance.
- Tell healthcare and anaesthesia teams about Wegovy before surgery or deep sedation, and verify pregnancy, breastfeeding, oral-medicine and licensed-supply instructions in the exact local leaflet.
Seek urgent medical help for severe persistent abdominal pain that may radiate to the back, serious allergy or breathing difficulty, fainting, severe low-glucose symptoms, sudden loss of vision or rapidly worsening eyesight. Repeated vomiting, inability to keep fluids down, dehydration signs, severe or persistent stomach problems, gallbladder-type symptoms or another concerning change needs prompt clinical advice. Do not stop, restart, increase, combine, crush, convert or switch Wegovy forms from this page.
Why your timeline may differ
Questions to ask before treatment
- Which country, Wegovy form, age group, indication and label revision apply?
- When did each symptom begin relative to treatment start or a clinician-directed change?
- Can food and fluids be kept down, and are urine, dizziness or daily function changing?
- Are insulin, a sulfonylurea, retinopathy, severe gastroparesis or planned surgery relevant?
- Is there severe persistent pain, serious allergy, severe low glucose or sudden vision loss?
Wegovy contains semaglutide across forms, but indications, ages, instructions, frequencies and presentations change by country and route. Keep injection and tablet data separate and use the official information where the product is dispensed.
Find official checks for 12 marketsHow this guide was made
6 named sources support the main claims. Each link explains how it was used, with public agencies, professional bodies or primary research preferred.
AI may assist with research organization, drafting and translation, but it is not treated as a source or credential. Read the editorial standards.
Stage bars organize a relative sequence. Original editorial illustrations are conceptual and are not clinical measurements, outcome percentages or personal forecasts.
This version has editorial evidence review, not medical review attributed to a named clinician. It does not replace an individual assessment. Editorial accountability.
Sources
- FDA: U.S. Wegovy Prescribing Information (June 2026)
Current combined U.S. injection and tablet indications, age boundaries, common reactions, warnings and form-specific clinical data.
- UK eMC: Wegovy Injection Patient Information Leaflet
Current U.K. injection wording for common digestive effects, dehydration, glucose, retinopathy, pancreatitis, gallbladder, NAION, surgery and other safety contexts.
- UK eMC: Wegovy Tablets Patient Information Leaflet
Current U.K. adult tablet wording, form-specific common effects, interactions, pregnancy, surgery and urgent warning signs.
- UK MHRA: First GLP-1 Tablet for Weight Management
June 2026 authorization context confirming the separate U.K. adult oral Wegovy form and common gastrointestinal effects.
- UK MHRA: Semaglutide and Very-Rare NAION Risk
U.K. safety communication on sudden painless vision loss or rapidly worsening eyesight and urgent assessment.
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Risks involving unapproved, compounded, fraudulent and counterfeit products, dosing errors, storage and licensed supply.
Frequently asked questions
What should I know about Wegovy Side Effects?
Common Wegovy side effects are mainly gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal symptoms appear prominently in current product information, alongside effects such as headache and fatigue. But there is no single worldwide Wegovy rate: the United States and United Kingdom now have separate injection and tablet contexts, and the U.S. adolescent weight-management evidence applies to injection rather than tablets. Severe persistent abdominal pain, serious allergy, inability to keep fluids down, severe low glucose in a relevant medicine combination, or sudden or rapidly worsening vision needs prompt or urgent assessment.
Why can the timeline differ from person to person?
Treatment type, depth, technique, anatomy, skin and tissue response, health history, medication, aftercare and complications can all change timing. The treating professional’s instructions take priority over a general guide.
When should I contact a professional?
Seek urgent medical help for severe persistent abdominal pain that may radiate to the back, serious allergy or breathing difficulty, fainting, severe low-glucose symptoms, sudden loss of vision or rapidly worsening eyesight. Repeated vomiting, inability to keep fluids down, dehydration signs, severe or persistent stomach problems, gallbladder-type symptoms or another concerning change needs prompt clinical advice. Do not stop, restart, increase, combine, crush, convert or switch Wegovy forms from this page.
Continue through the Wegovy evidence map
Keep route-, country- and age-specific side effects beside the class timeline and current product comparisons without turning any page into a prescription change.
Compare the class-wide side-effects timeline Compare Zepbound and Wegovy Compare Wegovy and OzempicExplore the complete GLP-1 beauty and body guide
Move between product identity, side-effect timing, facial documentation, hair-loss evidence, exercise safety and private tools without turning appearance into a diagnosis or prescription decision.
Open the GLP-1 topic hub Read the GLP-1 side-effects timelineRelated beauty guides
View BodyLiposuction Recovery Timeline: Week 1 to Month 6
A visual guide to bruising, swelling, activity limits and when body-contour results become easier to see after liposuction.
Read next BODYNonsurgical Body Contouring: Recovery and Results Timeline
Compare fat freezing, heat, ultrasound and magnetic body-contouring timelines, side effects, results and device-specific risks.
Read next BODYMounjaro Face: Facial Volume Changes, Evidence and Options
What ‘Mounjaro face’ means, why facial volume may change with substantial weight loss, what evidence can and cannot prove, and how to plan a qualified review.
Read nextThis guide is for general education only. It is not medical advice, diagnosis, a treatment recommendation or a prediction of individual results. BeautiNext is not a clinic. Seek care from an appropriately qualified professional.